Advancing gene therapy development with a multi-serotype AAV affinity resin

AAV purification poses a number of unique challenges to viral vector manufacturers including the need for scalability, a significant impurity burden, and ensuring a good recovery yield. In this article, a multi-serotype AAV affinity resin will be described and its use illustrated by relevant experiences and case studies from a CMDO developing an AAV purification platform for application across various AAV serotypes and client processes.

Please enter your email to access content Read now